



March 30, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001**

✓ **The National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051**

**Dear Sir/Madam,**

**Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Subject: U.S. FDA Inspection of the Company's Manufacturing Facility at Pithampur Unit-2**

We would like to inform that U.S. FDA inspected Lupin's Pithampur Unit-2 manufacturing facility from March 21 to March 29, 2023. The inspection closed with issuance of a Form-483 with ten observations.

We are addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance with utmost importance across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**